{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T02:26:13Z","timestamp":1782181573180,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:00:00Z","timestamp":1608076800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:00:00Z","timestamp":1608076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s00393-020-00938-5","type":"journal-article","created":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T08:04:43Z","timestamp":1608105883000},"page":"149-157","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Infektionsprophylaxe bei rheumatologischen Erkrankungen","Infection prophylaxis in rheumatic diseases"],"prefix":"10.1007","volume":"80","author":[{"given":"Christian","family":"Kneitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Kr\u00fcger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,16]]},"reference":[{"key":"938_CR1","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1016\/S0140-6736(20)31142-9","volume":"395","author":"DK Chu","year":"2020","unstructured":"Chu\u00a0DK et al (2020) Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV\u20112 and COVID-19: a\u00a0systematic review and meta-analysis. Lancet 395:1973\u20131987","journal-title":"Lancet"},{"key":"938_CR2","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1002\/art.10524","volume":"46","author":"MF Doran","year":"2002","unstructured":"Doran\u00a0MF, Crowson\u00a0CS, Pond\u00a0GR, O\u2019Fallon\u00a0WM, Gabriel\u00a0SE (2002) Frequency of infection in patients with rheumatoid arthritis compared with controls: a\u00a0population-based study. Arthritis Rheum 46:2287\u20132293","journal-title":"Arthritis Rheum"},{"issue":"5","key":"938_CR3","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/acr.23426","volume":"70","author":"NA Accortt","year":"2018","unstructured":"Accortt\u00a0NA, Lesperance\u00a0T, Liu\u00a0M et\u00a0al (2018) Impact of Sustained Remission on the Risk of Serious Infection in Patients With Rheumatoid Arthritis. Arthritis Care Res 70(5):679\u2013684","journal-title":"Arthritis Care Res"},{"issue":"10","key":"938_CR4","doi-asserted-by":"publisher","first-page":"e110066","DOI":"10.1371\/journal.pone.0110066","volume":"9","author":"X Pu\u00e9chal","year":"2014","unstructured":"Pu\u00e9chal\u00a0X, G\u00e9nin\u00a0E, Bienvenu\u00a0T et al (2014) Poor Survival in Rheumatoid Arthritis Associated with Bronchiectasis: A Family-Based Cohort Study. Plos One 9(10):e110066","journal-title":"Plos One"},{"key":"938_CR5","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S1473-3099(02)00437-1","volume":"2","author":"G Gavazzi","year":"2002","unstructured":"Gavazzi\u00a0G, Krause\u00a0HK (2002) Ageing and infection. Lancet Infect Dis 2:659\u2013666","journal-title":"Lancet Infect Dis"},{"key":"938_CR6","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1136\/ard.2011.151043","volume":"70","author":"A Strangfeld","year":"2011","unstructured":"Strangfeld\u00a0A, Eveslage\u00a0M, Schneider\u00a0M et al (2011) Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 70:1914\u20131920","journal-title":"Ann Rheum Dis"},{"key":"938_CR7","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1136\/annrheumdis-2011-200702","volume":"71","author":"WG Dixon","year":"2012","unstructured":"Dixon\u00a0WG, Abrahamowicz\u00a0M, Beauchamp\u00a0ME et\u00a0al (2012) Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a\u00a0nested case\u2013control analysis. Ann Rheum Dis 71:1128\u20131133","journal-title":"Ann Rheum Dis"},{"key":"938_CR8","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1136\/annrheumdis-2017-212861","volume":"77","author":"A Kronbichler","year":"2018","unstructured":"Kronbichler\u00a0A, Kerschbaum\u00a0J, Gopaluni\u00a0S et al (2018) Trimethoprim\u2013sulfamethoxazole prophylaxis prevents severe\/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 77:1440\u20131447","journal-title":"Ann Rheum Dis"},{"key":"938_CR9","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/annrheumdis-2017-212588","volume":"7","author":"KL Winthrop","year":"2018","unstructured":"Winthrop\u00a0KL, Baddley\u00a0JW (2018) Pneumocystis and glucocorticoid use: to prophylax or not to prophylax (and when?); that is the question. Ann Rheum Dis 7:631\u2013633","journal-title":"Ann Rheum Dis"},{"key":"938_CR10","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/annrheumdis-2017-211796","volume":"77","author":"JW Park","year":"2018","unstructured":"Park\u00a0JW, Curtis\u00a0JR, Moon\u00a0J, Song\u00a0YW, Kim\u00a0S, Lee\u00a0EBP (2018) Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis 77:644\u2013649","journal-title":"Ann Rheum Dis"},{"key":"938_CR11","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00393-018-0488-4","volume":"77","author":"B Ehrenstein","year":"2018","unstructured":"Ehrenstein\u00a0B (2018) Interpretation of tuberculosis and hepatitis screening before immunosuppressive treatment. Z\u00a0Rheumatol 77:493\u2013507","journal-title":"Z Rheumatol"},{"key":"938_CR12","first-page":"401","volume":"58","author":"X Puechal","year":"2019","unstructured":"Puechal\u00a0X, Judici\u00a0M, Calich\u00a0AL et al (2019) Rituximab for induction and maintenance therapy of granulomatosis with polyangiitis: a\u00a0single-centre cohort study on 114\u00a0patients. Baillieres Clin Rheumatol 58:401\u2013409","journal-title":"Baillieres Clin Rheumatol"},{"key":"938_CR13","series-title":"print","volume-title":"Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases, epub ahead of","author":"S Wijetilleka","year":"2019","unstructured":"Wijetilleka\u00a0S, Jayne\u00a0DR, Mukhtyar\u00a0C et\u00a0al (2019) Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases, epub ahead of. print, Bd. 2019"},{"key":"938_CR14","doi-asserted-by":"publisher","unstructured":"St\u00e4ndige Impfkommission (2019) Empfehlungen der St\u00e4ndigen Impfkommission (STIKO) am Robert Koch-Institut. Epid Bull 34:313\u2013364. https:\/\/doi.org\/10.25646\/6233.7","DOI":"10.25646\/6233.7"},{"key":"938_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","volume":"79","author":"V Furer","year":"2020","unstructured":"Furer\u00a0V, Rondaan\u00a0C, Heijstek\u00a0M et\u00a0al (2020) (2019) 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 79:39\u201352","journal-title":"Ann Rheum Dis"},{"key":"938_CR16","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/s00296-011-1808-z","volume":"32","author":"M Feuchtenberger","year":"2012","unstructured":"Feuchtenberger\u00a0M, Kleinert\u00a0S, Schwab\u00a0S, Roll\u00a0P, Scharbatke\u00a0EC, Ostermeier\u00a0E, Voll\u00a0RE, Sch\u00e4fer\u00a0A, Tony\u00a0HP (2012) Vaccination survey in patients with rheumatoid arthritis: a\u00a0cross-sectional study. Rheumatol Int 32:1533\u20131539","journal-title":"Rheumatol Int"},{"key":"938_CR17","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00296-016-3608-y","volume":"37","author":"M Krasselt","year":"2017","unstructured":"Krasselt\u00a0M, Ivanov\u00a0JP, Baerwald\u00a0C, Seifert\u00a0O (2017) Low vaccination rates among patients with rheumatoid arthritis in a\u00a0German outpatient clinic. Rheumatol Int 37:229\u2013237","journal-title":"Rheumatol Int"},{"key":"938_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s00103-019-02905-1","volume-title":"Impfen bei Immundefizienz Bundesgesundheitsbl doi.org","author":"N Wagner","year":"2019","unstructured":"Wagner\u00a0N et\u00a0al (2019) Impfen bei Immundefizienz Bundesgesundheitsbl doi.org https:\/\/doi.org\/10.1007\/s00103-019-02905-1"},{"key":"938_CR19","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1016\/j.vaccine.2020.01.037","volume":"38","author":"J Uziel","year":"2020","unstructured":"Uziel\u00a0J, Moshe\u00a0V, Onozo\u00a0B et\u00a0al (2020) Live attenuated MMR\/V booster vaccines in children with rheumatic diseases on immunosuppressive therapy are safe: Multicenter, retrospective data collection. Vaccine 38:2198\u20132201","journal-title":"Vaccine"},{"key":"938_CR20","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.autrev.2010.12.003","volume":"10","author":"S van Assen","year":"2011","unstructured":"van Assen\u00a0S, Elkayam\u00a0O, Agmon-Levin\u00a0N et al (2011) Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a\u00a0systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. Autoimmun Rev 10:341\u2013352","journal-title":"Autoimmun Rev"},{"key":"938_CR21","series-title":"Am","first-page":"1","volume-title":"Vaccines and Disease-Modifying Antirheumatic Drugs: Practical Implications for the Rheumatologist. Rheum Dis Clin North","author":"MA Friedman","year":"2017","unstructured":"Friedman\u00a0MA, Winthrop\u00a0KL (2017) Vaccines and Disease-Modifying Antirheumatic Drugs: Practical Implications for the Rheumatologist. Rheum Dis Clin North. Am, Bd. 43, S 1\u201313"},{"key":"938_CR22","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3899\/jrheum.170710","volume":"45","author":"S Subesinghe","year":"2018","unstructured":"Subesinghe\u00a0S, Bechman\u00a0K, Rutherford\u00a0AI (2018) A Systematic Review and Metaanalysis of Antirheumatic Drugs and Vaccine Immunogenicity in Rheumatoid Arthritis. J\u00a0Rheumatol 45:733\u2013744","journal-title":"J Rheumatol"},{"key":"938_CR23","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s10067-019-04857-y","volume":"39","author":"JK Park","year":"2020","unstructured":"Park\u00a0JK, Mj\u00a0KCY et al (2020) Effect of short-term methotrexate discontinuation on rheumatoid arthritis disease activity: post-hoc analysis of two randomized trials. Clin Rheumatol 39:375\u2013379","journal-title":"Clin Rheumatol"},{"key":"938_CR24","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.jaad.2017.09.076","volume":"78","author":"KL Winthrop","year":"2018","unstructured":"Winthrop\u00a0KL, Korman\u00a0N, Abramovits\u00a0W et al (2018) T\u2011cell-mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment. J\u00a0Am Acad Dermatol 78:1149\u20131155","journal-title":"J Am Acad Dermatol"},{"key":"938_CR25","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13075-019-1883-1","volume":"21","author":"KL Winthrop","year":"2019","unstructured":"Winthrop\u00a0KL, Bingham\u00a0CO III, Komocsar\u00a0WJ et al (2019) Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a\u00a0long-term extension trial substudy. Arthritis Res Ther 21:102","journal-title":"Arthritis Res Ther"},{"key":"938_CR26","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/RHU.0000000000000877","volume":"25","author":"S Intongkam","year":"2019","unstructured":"Intongkam\u00a0S, Samakarnthai\u00a0P, Pakchotanon\u00a0R et al (2019) Efficacy and safety of hepatitis B vaccination in rheumatoid arthritis patients receiving disease-modifying antirheumatic drugs and\/or biologics therapy. J\u00a0Clin Rheumatol 25:329\u2013334","journal-title":"J Clin Rheumatol"},{"key":"938_CR27","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.vaccine.2015.12.029","volume":"34","author":"KB Hertzell","year":"2016","unstructured":"Hertzell\u00a0KB, Pauksens\u00a0K, Rombo\u00a0L et al (2016) Tick-Borne encephalitis (TBE) vaccine to medically immunosuppressed patients with rheumatoid arthritis: a\u00a0prospective, open-label, multi-centre study. Vaccine 34:650\u2013655","journal-title":"Vaccine"},{"key":"938_CR28","first-page":"1","volume":"10","author":"M Rivera-Izquierdo","year":"2020","unstructured":"Rivera-Izquierdo\u00a0M, Valero-Ubierna\u00a0MC, Nieto-Gomez\u00a0P et al (2020) Vaccination in patients under monoclonal antibody treatment: an updated comprehensive review. Expert Rev Vaccines 10:1\u201318","journal-title":"Expert Rev Vaccines"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-020-00938-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-020-00938-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-020-00938-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T11:09:57Z","timestamp":1697368197000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-020-00938-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,16]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["938"],"URL":"https:\/\/doi.org\/10.1007\/s00393-020-00938-5","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,16]]},"assertion":[{"value":"16 December 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>C.\u00a0Kneitz<\/b>: A.\u00a0Finanzielle Interessen: Vortragshonorare: AbbVie, Biogen, Celltrion, Chugai, Gilead, GSK, Janssen, Lilly, Medac, MSD, Novartis, Pfizer, Roche, Sanofi, UCB.\u00a0\u2013 Bezahlter Berater\/interner Schulungsreferent\/Gehaltsempf\u00e4nger o.\u202f\u00c4.: AbbVie, Celltrion, Chugai, Gilead.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Chefarzt, Klinikum S\u00fcdstadt Rostock bis 2018, seitdem niedergelassener Rheumatologe\u00a0| Mitgliedschaften: Vorstand Verband der rheumatologischen Akutkliniken bis 2018, Vorsitzender Regionalverband Mecklenburg-Vorpommern im BDRH. <b>K.\u00a0Kr\u00fcger<\/b>: A.\u00a0Finanzielle Interessen: Vortragshonorare: AbbVie, Biogen, BMS, Celgene, Janssen, Lilly, Medac, MSD, Novartis, Pfizer, Roche, Sanofi, UCB.\u00a0\u2013 Beratungst\u00e4tigkeit: AbbVie, BMS, Celgene, Hexal, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Niedergelassener Internist und Rheumatologe\u00a0\u2013 eigenes Praxiszentrum M\u00fcnchen\u00a0| Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Rheumatologie, Berufsverband der Rheumatologen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}